The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma

被引：0
作者：
D Kube
T-D Hua
M Klöss
B Kulle
J Brockmöller
L Wojnowski
M Löffler
M Pfreundschuh
L Trümper
机构：
[1] Universitätsmedizin der Georg-August-Universität,Department of Hematology and Oncology
[2] Institute of Medical Informatics,Department of Statistics and Epidemiology
[3] University of Leipzig,Department of Pharmacology and Toxicology
[4] Institute of Epidemiology,Department of Internal Medicine I
[5] Universitätsmedizin der Georg-August-Universität,undefined
[6] Section of Statistics,undefined
[7] Institute of Basic Medical Science,undefined
[8] University of Oslo,undefined
[9] Universitätsmedizin der Georg-August-Universität,undefined
[10] Institute of Pharmacology,undefined
[11] University Mainz,undefined
[12] Saarland University,undefined
[13] Homburg/Saar for the DSHNHL (German High Grade NHL study group),undefined
来源：
Genes & Immunity | 2007年 / 8卷
关键词：
IL-10; polymorphisms; non-Hodgkin's lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Interleukin 10 (IL-10) gene is highly polymorphic, and the IL-10−1087AG (rs1800896) gene variation is the only so far studied intensively in association with certain diseases. Conflicting data have been published about an association of IL-10−1087AG gene variation with lower rates of complete remission and lower overall survival (OS) in patients with diffuse large B-cell lymphoma. To further investigate this in malignant lymphoma, we established the IL-10 genotypes in patients from the NHL-B1/ B2 studies from the German High-Grade Non-Hodgkin's Lymphoma Study Group. In our study, allele frequencies of lymphoma patients are comparable as in healthy controls. No increase of IL-10–1087G alleles was found. In addition we did not find any difference in OS or event-free survival between patients with IL-10–1087AA and the other genotypes. Comparable results were obtained for the IL-10 loci at −3538 (A/T), −1354 (A/G), −824 (C/T) and −597 (A/C) (rs1800890, rs1800893, rs1800871 and rs1800872).
引用
收藏
页码：164 / 167
页数：3
相关论文
共 104 条
[1]  
Moore KW(2001)Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol 19 683-765
[2]  
de Waal Malefyt R(1995)Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis Blood 85 2516-2520
[3]  
Coffman RL(1994)Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma Br J Haematol 88 770-777
[4]  
Cortes JE(1993)Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor Blood 82 2169-2174
[5]  
Talpaz M(1997)B-cell-derived IL-10: production and function Methods 11 98-111
[6]  
Cabanillas F(1998)IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis Rheumatic Dis Clin 24 629-639
[7]  
Stasi R(1998)Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy J Rheum 25 1874-1879
[8]  
Zinzani PL(1998)Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria J Infect Dis 178 520-525
[9]  
Galieni P(1999)Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival Ann Oncol 10 433-440
[10]  
Blay JY(1997)Interleukin-10. Actions and therapeutic potential BioDrugs 7 6-14
12345678910